RecruitingPhase 1NCT06872112

A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension

Phase I Study: A Dose-Escalation Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension

Sponsor

Joseph C. Wu

Enrollment

15 participants

Start Date

Jan 1, 2026

Study Type

INTERVENTIONAL

Conditions

Pulmonary Arterial Hypertension PAH

Summary

This is a 20-week, Phase 1, single-center, open-label, dose-escalation study evaluating the safety and tolerability of daily oral artesunate in patients with PAH.

Eligibility

Min Age: 18 YearsMax Age: 60 Years

Inclusion Criteria3

Each participant must meet the following criteria to be enrolled in this study:
Adults aged 18 to 75 years.
WHO functional class I, II/III despite treatment with maximally tolerated doses of 2 or more treatment modalities including PDE5 inhibitors, guanylate cyclase stimulators, endothelin receptor antagonists, and prostanoids when appropriate.

Exclusion Criteria2

Participants who meet any of the following criteria will be excluded from the study.
Participants with serious concomitant morbidity per investigator assessment.

Interventions

DRUGArtesunate

Participants will receive artesunate capsules. Participants will receive artesunate capsules TID in a dose escalation manner (60 mg, 120 mg, 180 mg total daily).